"inadequate efficacy" is a correct and usable expression in written English.
It can be used to describe a situation in which something is not working or achieving the desired result. For example: "The drug showed inadequate efficacy in treating the patient's illness."
Most patients (76.1%) were inadequately managed with anticholinergics due to inadequate efficacy.
Patients remain inadequately treated, because existing therapies have a number of shortcomings, including inadequate efficacy in glucose lowering, limited durability of glycemic response, inconvenient dosing regimens, and safety and tolerability issues.
We discuss issues implicated in inadequate efficacy, variability of responsiveness, and poor retention of benefit, while recommending design and conceptual refinements for future trials of cerebral neuromodulation in management of chronic neuropathic pain.
In a multinomial logistic regression model that examined predictors of subtypes of non-completion, subjects who entered the study as an inpatient were less likely to complete because of inadequate efficacy as determined by the investigator, and older subjects were less likely to complete because of poorer tolerability.
Reasons for increased attrition rates in drug development include toxicity and inadequate efficacy due to individual variation in therapeutic response and development of drug resistance [2].
During the majority of this pilot programme, patients selected were typically those who could not use established acute migraine medications due to intolerable side effects, lack of efficacy or inadequate efficacy or they had medical contraindications to the medicines.
The current drugs to treat HAT are inadequate, due to poor efficacy, side effects and the requirement for parenteral administration, which is not appropriate for a rural African setting. 2 Folate metabolism has been successfully used as a drug target in a number of diseases such as cancer, bacterial infections and malaria.
The current drugs to treat HAT are inadequate due to poor efficacy, side effects and the requirement for parenteral administration, which is not appropriate for a rural African setting. 1, 2 Herein we report a target-based approach to the discovery of novel inhibitors of trypanothione reductase (TryR) as a potential therapy for HAT.
The current therapeutic arsenal against viral infections remains limited, with often poor efficacy and incomplete coverage, and appears inadequate to face the emergence of drug resistance.
Patients who experience the onset of inadequate therapeutic efficacy may be up-titrated in dose as per normal clinical practice.
Nowadays, the high failure rates in phases 2 and 3 are due to inadequate compound efficacy, and this is the most important determinant of overall drug development cost.
